» Articles » PMID: 7102898

Uterine Papillary Serous Carcinoma: a Highly Malignant Form of Endometrial Adenocarcinoma

Overview
Date 1982 Mar 1
PMID 7102898
Citations 105
Authors
Affiliations
Soon will be listed here.
Abstract

A review of 256 cases of pathologic Stage I uterine adenocarcinoma treated at Stanford University Hospital revealed 26 cases of uterine papillary serous carcinoma (UPSC), a clinically aggressive and morphologically distinct variant of adenocarcinoma which closely resembles ovarian papillary serous carcinoma. These lesions are easily recognized by microscopic examination and typically feature a high degree of cytologic anaplasia and a papillary growth pattern. Invasion of the lymphatics has been a frequent finding. The relapse rate among patients with pathologic Stage I UPSC was 50% (13/26), five times the rate which would have been predicted by the incidence of UPSC. Patients with Stage I UPSC fared significantly worse than the group of nonpapillary grade II or grade III adenocarcinomas (p less than 0.0001). Forty percent of Stage I UPSC patients had deep myometrial invasion, as compared with 12% of those with all other histologic types of adenocarcinoma (p = 0.001). Women with UPSC deeply invading the myometrium tended to do worse than those with deeply invasive lesions of the more usual endometrioid type as reflected by relapse rates (after surgery alone) of 63% and 30%, respectively. Of seven Stage I corpus carcinoma patients whose initial site of failure was in the upper abdomen, six had UPSC. Thus, UPSC shares the tendency of its ovarian counterpart to spread over peritoneal surfaces. In addition to the original study group of 26 Stage I patients, 34 patients with more advanced stages of UPSC were also reviewed. Of these, 26 have been followed and four survive. Eleven of these women presented or relapsed with abdominal carcinomatosis. UPSC is a clinically aggressive neoplasm which should be distinguished from other types of primary endometrial adenocarcinoma. In cases of invasive UPSC the mode of spread, similar to that of ovarian surface epithelial carcinomas, suggests the need for adjuvant upper abdominal and pelvic irradiation or effective chemotherapy.

Citing Articles

Unraveling the Heterogeneity of Deficiency of Mismatch Repair Proteins in Endometrial Cancer: Predictive Biomarkers and Assessment Challenges.

Carvalho F, Carvalho J Cancers (Basel). 2024; 16(20).

PMID: 39456546 PMC: 11505891. DOI: 10.3390/cancers16203452.


An unusual uterine papillary serous carcinoma with post therapy disseminating metastasis presenting as primary renal malignancy: a case report.

Liu K, Chang Y, Lin Y, Chang J Ann Med Surg (Lond). 2024; 86(1):456-462.

PMID: 38222732 PMC: 10783217. DOI: 10.1097/MS9.0000000000001574.


The Identification of Gamma-Glutamyl Hydrolase in Uterine Corpus Endometrial Carcinoma: a Predictive Model and Machine Learning.

Zhu C, Du Y, Huai Q, Fang N, Xu W, Yang J Reprod Sci. 2023; 31(2):532-549.

PMID: 37798609 DOI: 10.1007/s43032-023-01363-0.


Development and Perspectives: Multifunctional Nucleic Acid Nanomedicines for Treatment of Gynecological Cancers.

Korzun T, Moses A, Diba P, Sattler A, Olson B, Taratula O Small. 2023; 20(41):e2301776.

PMID: 37518857 PMC: 10827528. DOI: 10.1002/smll.202301776.


Circulating and Endometrial Tissue microRNA Markers Associated with Endometrial Cancer Diagnosis, Prognosis, and Response to Treatment.

Oropeza-de Lara S, Garza-Veloz I, Berthaud-Gonzalez B, Martinez-Fierro M Cancers (Basel). 2023; 15(10).

PMID: 37345024 PMC: 10216486. DOI: 10.3390/cancers15102686.